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Abstract 
 
 This is a cross-sectional hospital based study, aimed to study 
the effect of antiepileptic drugs on the thyroid function.  It was 
conducted in Gafaar Ibn Ouf and Omdurman Children’s 
Emergency Hospital referral clinics, in the period from April – July 
2006. 
 The total of 67 children with epilepsy, aged < 16 yrs and 30 
healthy children were taken as control, males were predominant 
(68.7%).  56 patients were on Carbamazepine  and 11 patients were 
on Sodium Valporate. 
 All children in the study group were surveyed and 
investigated for thyroid function by measuring serum T4, T3 and 
TSH levels. 
• Carbamazepine group had significantly low serum T4 
level (P = 0.00) and significantly higher T3 level (0.04) 
than control group. 
• TSH level had insignificant difference from control 
group. 
• Sodium Valporate group had insignificant difference in 
thyroid function from control. 
• Serum T4 level in Carbamazepine group affected by age 
but not affected by sex, origin and duration of treatment. 
• Serum T3 level in Carbamazepine affected by duration 
of treatment but not affected by sex, age or origin.   
• Almost all patients were clinically euthyroid. 
 
vi 
 
  ﻣﻠﺨﺺ  اﻻﻃﺮوﺣﺔ
 – ﻋﺎﻣﺎ 61 ﻃﻔﻼ ﻣﻦ ﻣﺼﺎﺑﻲ اﻟﺼﺮع واﻋﻤﺎرهﻢ اﻗﻞ ﻣﻦ 76ﺷﻤﻠﺖ اﻟﺪراﺳﺔ 
 ﻃﻔﻼ أﺻﺤﺎء اﻋﻤﺎرهﻢ اﻗﻞ ﻣﻦ 03ﺑﺎﻻﺿﺎﻓﺔ اﻟﻲ %( .  7.86)د اﻟﻤﺮﺿﻲ ﻻﻧﺴﺒﺔ اﻻو
  . ﻋﺎﻣﺎ آﻤﻘﻴﺎس 61
 ﻣﻨﻬﻢ 11 وﺧﻤﺴﻮن ﻃﻔﻼ ﻣﻦ اﻟﻤﺼﺎﺑﻴﻦ ﻳﺘﻌﺎﻃﻮن اﻟﻜﺎرﺑﻤﺎزﺑﻴﻦ و ﺳﺘﺔ
  .ﺮوات اﻟﺼﻮدﻳﻮمﺒﻠﻓﻳﺘﻌﺎﻃﻮن 
ﺖ هﺬﻩ اﻟﺪراﺳﺔ ﻟﻤﻌﺮﻓﺔ اﺛﺮ اﻻدوﻳﺔ اﻟﻤﻀﺎدﻩ ﻟﻠﺼﺮع ﻋﻠﻲ وﻇﺎﺋﻒ اﻟﻐﺪة اﺟﺮﻳ
  .اﻟﺪرﻗﻴﺔ
م ﺑﺎﻟﻌﻴﺎدات 6002ﺗﻤﺖ اﻟﺪراﺳﺔ ﻓﻲ اﻟﻔﺘﺮة ﻣﻦ اول اﺑﺮﻳﻞ ﺣﺘﻲ ﻧﻬﺎﻳﺔ ﻳﻮﻟﻴﻮ 
  .اﻟﻤﺤﻮﻟﺔ ﻓﻲ آﻞ ﻣﻦ ﻣﺴﺘﺸﻔﻲ ﺟﻌﻔﺮ ﺑﻦ ﻋﻮف وﺣﻮادث اﻣﺪرﻣﺎن ﻟﻼﻃﻔﺎل
اﻟﺪرﻗﻴﺔ ﺗﻢ رﺻﺪ آﻞ اﻻﻃﻔﺎل ﻣﺤﻮر اﻟﺪراﺳﺔ واﺟﺮي ﻟﻬﻢ ﻓﺤﺺ وﻇﺎﺋﻒ اﻟﻐﺪة 
 ,3T)واﻟﻬﺮﻣﻮن اﻟﺪرﻗﻲ (  HST) ﻟﻠﻐﺪة اﻟﺪرﻗﻴﺔ ﺤﺎث ﺑﻘﻴﺎس ﻣﺴﺘﻮي اﻟﻬﺮﻣﻮن اﻟ
  .(4T
 = P( )4T)وﺟﺪ ان هﻨﺎك اﻧﺨﻔﺎﺿﺎ ذا دﻻﻟﺔ اﺣﺼﺎﺋﻴﺔ ﻓﻲ ﻣﻌﺪل هﺮﻣﻮن اﻟﻐﺪة 
آﻤﺎ ان .  ﺔ ﺑﻤﻌﺪﻟﻪ ﻋﻨﺪ اﻻﺻﺤﺎءﻧﻋﻨﺪ اﻟﻤﺮﺿﻲ ﻣﺘﻌﺎﻃﻲ اﻟﻜﺎرﺑﻤﺎزﺑﻴﻦ ﻣﻘﺎر(  00.0
ﻣﻘﺎرﻧﺔ ( 3T)ﻓﻲ هﺮﻣﻮن اﻟﻐﺪة (  4.0 = P)ﻟﺪﻳﻬﻢ ارﺗﻔﺎع ذا دﻻﻟﺔ اﺣﺼﺎﺋﻴﺔ 
  . ﻣﻌﺪل اﻟﻬﺮﻣﻮن اﻟﺤﺎث ﻟﻠﻐﺪة اﻟﺪرﻗﻴﺔ ﻟﻢ ﻳﺘﺄﺛﺮ –ﺑﺎﻻﺻﺤﺎء 
  .ﺮوات اﻟﺼﻮدﻳﻮم ﻟﻢ ﺗﺘﺄﺛﺮ ﺒوﻇﺎﺋﻒ اﻟﻐﺪة اﻟﺪرﻗﻴﺔ ﻋﻨﺪ اﻟﻤﺮﺿﻲ ﻣﺘﻌﺎﻃﻲ ﻓﻠ
اآﻠﻴﻨﻴﻜﻴﺎ ﻻﺗﻮﺟﺪ اي اﻋﺮاض ﻟﻨﻘﺺ هﺮﻣﻮن اﻟﻐﺪة اﻟﺪرﻗﻴﺔ ﻋﻨﺪ آﻞ  •
 .اﻟﻤﺮﺿﻲ
ﻓﻘﻂ ﺑﻌﻤﺮ اﻟﻤﺮﺿﻲ وﻟﻢ ﺗﺄﺛﺮ ( 4T)ﻣﻌﺪل هﺮﻣﻮن اﻟﻐﺪة اﻟﺪرﻗﻴﺔ  •
 .ﻳﺘﺄﺛﺮ ﺑﺠﻨﺲ أو أﺻﻞ اﻟﻤﺮﺿﻲ أو ﻣﺪة اﻟﻤﻌﺎﻟﺠﺔ ﺑﺎﻟﺪواء
ﺗﺄﺛﺮ ﺑﺎﺧﺘﻼف ﻣﺪة اﺳﺘﻌﻤﺎل اﻟﺪواء وﻟﻢ ( 3T)ﻣﻌﺪل هﺮﻣﻮن اﻟﻐﺪة  •
  . اﻟﺠﻨﺲ أو اﺻﻞ اﻟﻤﺮض–ﻳﺘﺄﺛﺮ ﺑﻌﺎﻣﻞ اﻟﻌﻤﺮ 
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Chapter One 
1-  Introduction and Literature Review 
1.1 General consideration: 
The epilepsies are common and frequently devastating 
disorders, affecting approximately 2.5 million people in the 
United States alone(1).    At any one time 7 in 1000 people in 
the general population have epilepsy. Epilepsy usually begins 
in childhood, potentially impeding education, employment, 
social relationships and development of a sense of 
self-worth(2).  
History and examination, together with electroen- 
cephalography, will usually determine the epilepsy syndrome 
(category), forming the basis for any further investigation and 
possible antiepileptic therapy. Imaging may be required in 
some circumstances(2).    
  Compliance with medications is a major problem 
because of the need for long term therapy together with 
unwanted effects of many drugs(1).  One of these is its effects on 
thyroid function.  
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1.2 Definition: 
An epileptic fit may be defined as a brief disorder of 
cerebral function,  usually  associated  with  disturbance  of 
consciousness  and accompanied by a sudden electrical 
discharge of cerebral neurons(3) 
1.3 Epidemiology: 
Seizures are common neurological disorders in the 
pediatrics age group and occurs 3-5% of children . Epilepsy 
occurs in 0.5-1% of the population and begins in childhood in 
60% of cases .30.000 children and adolescent are diagnosed 
each year with epilepsy in the U.S.A( 4).  
1.3.1    Incidence: 
The incidence of epilepsy ranges from 40 to 70 per 
100.000 in most developed countries and from 100 to 190 per 
100.000 in developing countries (5,6).   
1.3.2     Prevalence and incidence in Sudan:   
 No data available from Sudan. 
 Khalid(8)  in this study found that males more affected than 
females 1.2 :1. Generalized seizures are the commonest type of 
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seizures, occurring in 73.4% of epileptic children. The average 
age of onset of seizures was 46.3 months. 
1.4 Etiological & predisposing factors(9): 
-   In many, perhaps the majority (60%) of cases, are 
cryptogenic or idiopathic (9, 10). 
-  Other factors:  Family history, trauma and surgery to the 
head,intracranialmasslesions,cerebralinfarction ,drugs(al
chol) and withdrawal, photosensitivity and auditory 
stimuli. 
1.5    Mechanisms of the disease:   
Epileptogenesis is a gradual process that can be 
specifically targeted(11). 
Current evidence suggests that generalized epilepsies 
originate from alterations in either network, as in absence 
seizures, or intrinsic neuronal function, as in  
channelopathies. Partial epilepsy syndromes, presumably, 
stem from a focal lesion. 
Newer avenues of study (such as cortical 
malformations) and newer conceptual mechanism (such as 
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the role of glial cells and neuronal micro-environment.  Many 
such malformations are associated with refractory epilepsy 
and are increasingly recognized as a common cause of 
epilepsy that was previously believed to be cryptogenic(12). 
The mechanism that generate absence epilepsy is now 
believed to involve an alteration in the circuitry between the 
thalamus and cerebralcortex(13,14). 
In addition to these morphologic features, changes at 
the molecular level may also be important. The most 
prominent of these are alterations in the composition and 
expression of GABAA receptors on the surface of hippocampal 
dentate granule cells(15).  
Mutant genes have been identified for the following: 
Generalized epilepsy with febrile seizures (GEFS+ve) {point 
mutation in SCNIB(16), two forms of benign familial 
neonatal convultions: KCNQ2 and KCNQ3(17-19); and 
frontal lobe epilepsyCHRNA4(20) .  
1.6 Classification(21-25):   
 There are many classifications: 
a) International classification of epileptic seizures. 
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1) Partial seizures: 
a)    Simple partial (consciousness retained): 
-    Motor  -    Sensory      -    Autonomic     -    
Psychic  
b)    Complex partial (Consciousness impaired): 
-    Simple partial followed by impaired 
consciousness. 
-   Consciousness impaired at onset. 
c)    Partial seizures with secondary generalization. 
2) Generalized seizures: 
A- Absence seizures      b- Atypical absence seizures  
B-  Generalized tonic clonic.  
C- Tonic      D- Clonic      E-   Myoclonic   
F- Atonic        G- Infantile spasm. 
3) Unclassified seizures. 
Epilepsy in children has also been classified by 
syndromes. Using the age at onset of seizures, cognitive 
development and neurologic examination, description of 
seizure type, and EEG findings including the background 
rhythm. It has been possible to classify approximately 50% 
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of childhood seizures into specific syndromes. 
The syndromic classification of seizures provides a 
distinct advantage over previous classification by 
improving management with the appropriate 
anti-convulsant medication, identifying potential 
candidates for epilepsy surgery and providing patients and 
families with a reliable and accurate prognosis. 
Example of epilepsy syndromes include: Infantile 
spasm (West Syndrome), Benign myoclonic epilepsy of 
infancy, the Lennox-Gastaut syndrome, febrile 
convulsions, Landau - Kleffner syndrome, Benign 
childhood epilepsy with centrotemporal spikes (Rolandic 
epilepsy), Rasmussen encephalitis, Juvenile myoclonic 
epilepsy (Janz syndrome), and Lafora disease (Progressive 
myoclonic epilepsy). 
b) The abbreviated International League against Epilepsy 
classifications of epilepsies & epileptic syndromes: 
1) Generalized epilepsies and syndromes: 
o Idiopathic with age related onset: 
? Benign neonatal convulsions 
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? Childhood absence epilepsy 
? Benign myoclonic epilepsy in infancy 
? Juvenile myoclonic epilepsy 
? Epilepsy with generalized tonic-clonic 
seizures in awakening 
? Symptomatic or cryptogenic: 
• West syndrome 
• Lennox – Gastaut syndrome 
? Symptomatic: 
? Early myoclonic encephalopathy. 
(ii) Localization – related epilepsies and syndromes: 
? Idiopathic with age related onset: 
o Rolandic epilepsy 
o Childhood epilepsy with occipital 
paroxysms 
? Sympotomatic: 
o Epilepsy with simple partial, complex 
partial or secondarily generalized seizures. 
(iii) Epilepsies and syndromes undetermined focal or 
generalized. 
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? Severe myoclonic epilepsy in infancy.  
(iv) Special syndromes: 
1.7 Differential Diagnosis(23, 25-28): 
a) Nonepileptic events mimicking epileptic seizures: 
Syncope, Cardiacarrythmia, Breathholdingspells, 
Psychogeni non-epilepticseizures. Familial paroxysmal 
choreoathetosis, Shuddering attacks, and Narcolepsy 
and cataplexy 
b) True epileptic seizures caused by a non-neurological 
conditions:  
i- Febrile seizures,  
ii- Metabolic disorders,  
iii- CNS infection,  
iv- Sleep deprivation,  
v- Alcohol or drug withdrawal.  
vi- Drug abuse.  
vii- Acute traumatic seizures. 
viii-  Benign paroxysmal vertigo. 
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1.8     Clinical Features(3,22,25): 
(1) Grand-mal Epilepsy: 
? Tonic phase: sudden loss of consciousness, limbs 
extend, back arches, teeth clench, breathing 
stops.  Tongue may be bitten. Lasts about 20 – 30 
sec. 
? Clonic phase:  intermittent jerking movements, 
irregular breathing, mutation and salivation.  
? Post-ictal phase:  child sleeps and disoriented. 
(2) Simple absence seizures (petit-mal): 
 Fleeting impairment of consciousness (day dreaming), 
no falling or abnormal movements. 
(3) Myoclronic seizures: 
 Stroke-like jerks, often causing sudden falls usually 
occurs in children with a structural neurological or cerebral 
degenerative condition. 
(4) Simple partial seizures: 
 Twitching or jerking of face, arms or leg – 
consciousness usually retained.  Jacksonian pattern (starts 
focally and spreads) 
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 Temporary weakness of involved part of the body after 
attack. 
 May progress to full-blown tonic-clonic attacks. 
(5) Complex partial seizures (temporal lobe) 
 Altered or impaired consciousness associated with 
strange sensations, hallucinations or semi-purposeful 
movements. 
 Post- octal phase with amnesia. 
(6) Infantile spasm: 
 Onset at 3-8 months of age.  
Flexion spasms (Jacknife or  Salaam seziures) 
Lasts for few seconds, occur in clusters. 
Regression of developmental skills 
History of perinatal asphyxia or meningitis. 
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1.9 Diagnosis and Management: 
The first step in epilepsy management is identification 
of the syndrome.. Syndrome determination hinges on 
seizure description and frequency, age at onset, 
neurological history and functional enquiry, neurological 
exam and one or more EEGs.   Neuro-imaging   may   aid   in   
evaluation,   but   most syndromes are defined by the 
mentioned means(2,3,22). 
Drug therapy is indicated to treat epilepsy when there 
is increased likelihood of seizure recurrence and usually 
after the second unprovoked seizure (Excluding febrile 
seizure). For most patients, the use of a single anti-epileptic 
drugs (Monotherapy) results in higher compliance rate, 
wider therapeutic window, and is more efficient than 
polytherapy in addition to producing fewer adverse effect (24). 
The rational therapeutic approach consists of selecting the 
medication according to patient characteristics, taking into 
account the type of seizure, epilepsy syndrome, individual 
peculiarities, availability or cost of medication (29). 
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1.10 Anti-epileptic drugs: 
The chemical structures of most of the drugs 
introduced before 1965 were closely related to 
phenobarbital these include the hydantoins, 
oxazolindinediones, and the succinides. 
The agents introduced after 1965 exhibit a diversity of 
chemical structures. These include benzodiazepines 
(clonazepam & clonazepate) an imino stilbene 
carbamazepine (CBZ), branched chain carboxylic acid 
(valproic acid), a phenytriazine (lamotrigine), acyclic 
analogous of GABA (Gabapentin) asulfamate, substituted 
monosachride (Topiramate), anipecotic acid derevative 
(Tiagabine) and apyrolidine denerative (Levertractor) (1). 
Drugs effective against the most common forms of 
epileptic seizures, partial and secondarily generalized 
tonic-clonic seizures, appear to work by one of two 
mechanisms. One is to limit the sustained, repetitive firing 
of a neuron, an effect mediated by promoting the in 
activated stage of voltage activated Na+ channels. 
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A second mechanism appears to involve enhanced 
GABA-mediated synaptic inhibition, an effect mediated by 
an action presyanptically for some drugs and post 
-synaptically for others drugs.   Effective against a less 
common form of epilepsy (Absence seizures) limit activities 
of a particular voltage activated Ca+ channel known as the 
T current(1,30).  
1.10.1 Carbamazepine: (Tegretol): 
Was initially approved in the U.S for use as an 
anti-seizure agent in 1974. It is now considered to be a 
primary drug for the treatment of partial and tonic-clonic 
seizures, chemically it is related to the tricyclic 
anti-depressants(1). 
1.10.1.1 Pharmacological effects: 
- CBZ have been found to produce therapeutic 
responses in manic depressive patients. 
- Anti-seizure effect without causing general depression 
of CNS. Further, CBZ has anti diuretic effects that is 
sometimes associated with increase concentration of 
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antidiuretic hormone level in the plasma. 
- CBZ limits the repetitive firing of action potentials 
evoked by a sustained depolarization of a mouse spinal 
cord or cortical neurons maintained in vitro. 
- Trigeminal neuralgia(1,31,32).   
 1.10.1.2   Pharmacokinetic properties: 
CBZ is absorbed slowly and erratically after oral 
administration. Peak concentration in plasma is usually 
observed 4 - 8  hrs after oral ingestion, but may be 
delayed as much as 24 hr, specially following the 
administration of a large dose. It is distributed rapidly to all 
tissues.  Binding to plasma protein occurs to the extent of 
about 75%.  The predominant pathway of metabolism in 
human being involves conversion to the 10, 
11-epoxide(1,31,32). 
CBZ is inactivated by conjunction and hydroxylation. 
The hepatic cytochrome P450 isoform primarily responsible 
for biotransformation of CBZ is CYP3A4. CBZ induces 
CYP2C and CYP3A and also UDP-glucouronosyltransferse. 
Thus enhancing the metabolism of drug degraded by these 
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enzymes(1). 
Plasma   drug   concentration:   There   is   no   simple   
relationship between the dose and concentration of the drug 
in plasma. 
Therapeutic concentrations are reported to be 6-12 
microgram/mL, although considerable variations occur.   
Side effects referable to CNS are frequent at 9 
microgram/mL(1). 
1.10.1.3 Toxicity: 
• Dose related:  Gastric irritability. Diplopia or blurred 
vision; Dizziness, Drowsiness, ataxia, headache, 
tremors dystonia, chorea, depression, convulsions, 
irritability, psychosis, water retention, congestive heart 
failure, cardiac arrythmias. 
 Idiosyncratic:  anaemia, agranulocytosis, leucopenia, 
thrombocytopenia, hypersensitivity syndrome (Dermatitis, 
eosinophilia, lymphadenopathy and splenomegally and 
jaundice. 
- Interactions:  Affects and affected by other antiepilepstic 
drugs and other drugs e.g:Cimetidine Erythromycin 
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whichmay cause toxic elevations of serum 
carbamazapin( (1,30,31).. 
1.10.2 Valproic Acid: (Depakene) 
Was approved for use is U.S in 1978. It is a simple 
branched chain carboxylic acid (N-dipropyl acetic acid)(1). 
Mechanism of action: valproic acid produce effects on 
isolated neurons at therapeutically relevant concentrations, 
valproate inhibits sustained repetitive firing induced by 
depolarization of a mouse cortical or spinal cord neurons(33). 
The action appears to be mediated by a prolonged 
recovering of voltage activated and sodium channels from 
inactivation. In neurons isolated from distinct region, 
nodose ganglion, valproate reduces the low threshold (T) 
calcium current(33,34). 
It also increases the amount of GABA that can be 
recovered from the brain after the drug is administered to 
animals. In vitro, valproate can stimulate the activity of the 
GABA synthetic enzyme, glumatic acid decarboxylase (35) 
and inhibit GABA degredative enzymes, GABA trans- 
aminase and succinct semi aldehyle dehydrogenase (36).  
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1.10.2.1 Pharmacokinetic properties: 
-   Absorbed rapidly and completely after oral 
administration. 
-   Peak concentration in plasma is observed within 1-4 
hr, this can be delayed for several hrs if the drug is 
administered in enteric coated tablets or is ingested 
with meals. 90% bound to protein. 
The vast majority of valproate (95%) undergoes hepatic 
metabolism, with less than 5% excreted unchanged. Its 
hepatic metabolism occurs mainly by UGT enzymes and B 
oxidation. Valproate is a substrate for CYP2C9 and 
CYP2C19 but its metabolism by this enzymes accounts for a 
relatively minor portion of its elimination. 
The half-life of valproate is approximately 15hrs but is 
reduced in patient taking other antiepileptic drugs (1).  
1.10.2.2  Toxicity: 
The most common side effects are transient GIT 
symptoms in about 60% of patients. Effects on CNS include 
sedation, ataxia and tremor. It also causes rash, alopecia, 
stimulation of appetite. It has also several effects on hepatic 
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functions, increases liver enzymes in 40% of patients, rare 
complication is fulminant hepatitis (37), acute pancreatitis and 
hyperammonemia. 
The   concentration   of valproate   in plasma  that   is   
associated   with therapeutic effects is approximately 30-100 
microgram/mL(1)  
1.10.2.3 Druginteractionofvalproate: WithPhenytoin, 
Lamotrigine, Lorazepam,andClonazepam(1). 
1.10.2.4 Therapeutic uses: Valproate  is effective in the 
treatment of absence, myoclonic, partial and tonic-clonic 
seizures(31). 
1.11   Surgical Treatment: 
Surgical treatment can be an option for epilepsy when 
an underlying brain abnormality, such as a benign tumor or 
an area of scar tissue (e.g. hippocampal sclerosis) can be 
identified. Also it is offered to patients when their epilepsy 
has not been controlled by adequate attempts with 
multiple medications(38). 
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1.12   Other treatment: 
Ketogenic diets may occasionally be effective in 
controlling some types of epilepsy; although the 
mechanism behind the effect is not fully understood, 
shifting of pH towards a metabolic acidosis and alteration of 
brain metabolism may be involved.  Ketogenic diets are 
high in fat and extremely low in carbohydrates, with intake 
of fluids often limited(39).  
1.13   Prognosis of epilepsy: 
Thirty percent of patients have mild epilepsy that does 
not require treatment and remits within a short period; 
30% are easily controlled on AEDs; 20% have chronic 
epilepsy that responds only partially to AEDs and 20% 
have chronic unremitting epilepsy with little response to 
treatment.  
Syndromes: 
 Good prognosis:  Absence seizures, rolandic, benign 
idiopathic neonatal convulsions, benign epilepsies of 
childhood. 
 20
 Poor prognosis:  Infantile spasms, Lennox-Gastaut, 
Landau-Kleffner, severe myoclonic epilepsy of infancy 
1.14 Thyroid Hormones: 
 Thyroid hormones (T3 & T4) are synthesized in the 
thyroid gland by the iodination of the amino acid tyrosine(1). 
 The production of thyroid hormones is regulated by 
the hypothalamus and the pituitary gland.  
 T3 & T4 are carried largely bound to plasma protein 
principally thyroid hormone binding globulin, only about 
0.3% of T3 and 0.03% of T4 is transported free.  T4 is 
bound more tightly than T3 and its half life about 6 days 
whereas that of T3 is only one day.  In the tissues, 85%of 
T3(considered as the active hormone)is derived from T4 by 
the enzyme 5monodeiodoinase(40-43).  
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1.14.1 Diagnosis of thyroid abnormalities(41,42): 
1) Serum thyroid hormones: methods are available to 
measure all the thyroid hormones in serum T4,T3, 
FT4, free T3,  and TSH.  
2)  Serum thyroxine binding globulins (TBG).  
3) TRH stimulation test of TSH release. 
4) T3 suppression test. 
5) Thyroid ultrasonographic studies . 
 
1.14.2 Disorders of thyroid function(4,40,42): 
 Defects of thyroid function could be either hypo or 
hyperthyroidism. 
1.14.2.1 Hypothyroidism:  
It is either primary or secondary  
• Primary hypothyroidism: Results from deficient 
production of thyroid hormone or defect in thyroid 
hormonal receptor activity.  
• Congenital hypothyroidism:  sporadic and familial , 
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goitrous and non goitrus . In many  cases the 
deficiency occurs and manifestations may develop in 
the early weeks of life or may be delayed for months  
• Clinical features: Large anterior fontanels, coarse 
faces, umbilical hernia, lethargy and irritability, large 
tongue, coarse voice, retarded development and 
growth. 
Neonatal Period Early Symptoms:  
1) Prolonged gestation with large bulk weight 
2) Persistent jaundice 
3) Temperature instability. 
4) Delayed initial  bowel opening for >24hrs.                                          
5) Oedema 
6) Hypo activity and poor feeding 
Treatment should begin immediately after the 
diagnosis is established. Recommended dosage of synthetic 
thyroxine is 10 – 15 microg /kg for the newborn and less 
thereafter.           
• Acquired hypothyroidism: 
Occurs in 1 : 500 school age children, it carries no risk 
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of permanent mental retardation but temporary behavior 
changes are frequent ,as well as growth .  
Aetiology: 
1. Hashimotos thyroiditis  
2. Subacute thyroiditis  
3. Enviromental  causes: goitrogens ingesion, 
thyroidectomy, and radioactive iodineablative 
therapy. 
4. Infiltrative disease: eg  langherhans histocytosis 
Clinical features are: cold intolerance, constipation, 
weight gain, dry skin and sparse brittle hair.  Long 
standing hypothyroidism leads to enlargement of pituitary 
primary gland, poor growth (short stature), puberty is 
delayed or absent in teenage patients, precocious puberty 
occurs in some with delayed skeletal  and dental age, 
goiter muscular pseudohypetrophy (rare), absent menses, 
bradycardia and galactorrhea(rare).  
• Secandary hypothyroidism : Causes that lead to 
central hypothyrodism. 
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- Pituitary hypothalamic dysfunction 
- Hypopitutarism could be idiopathic or due to, 
head trauma, tumor, infiltrative disease, 
surgery or, radiation therapy. 
TSH deficiency is associated with generalized 
pituitary or hypothalamic dysfunction. Isolated TSH 
deficiency is rare and may be caused by  lack of TRH 
stimulus(receptor defect, tumor invasion of the critical 
hypothalamic nuclei  or idiopathic). 
1.14.2.2 Hyperthyroidism (4,40,42): 
Occurs when excessive amount of thyroid hormone 
is present. Hyperthyroidism in childhood is rare and 
accounts for fewer than 5% of all cases of hyperthyroidism.  
   Goiter, anxiousness, tachycardia, widened pulse 
pressure, increased appetite, weight gain or loss, tremor, 
proptosis, heat intolerance, increased growth velocity , 
diarrhea’, fatigue, sleep disturbance. 
• Congenital Hyperthyroidism (Neonatal 
Thyrotoxicosis): 
Occurs almost exclusively in infants of mothers with 
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Graves disease. Occurs in as many as 1 of 70 infants of 
mothers with Graves disease with equal gender 
distribution. 
The cause is the passage of TSI (maternal 
immunoglobulin) to the fetus.   The prolonged form may be 
caused by endogenously produced persistent (TSI) from 
infant’s own lymphocytes or from transplacentaly acquired 
maternal lymphocytes. 
 
• Acquired Hyperthyroidsm: 
Most often is caused by Graves disease, female : male 
is 3:1. It has familial tendency  and  an association  with 
HLA type  B8  and  DR3.  Thyroid hormone profile 
characteristically shows elevated total T4 ,free T4 and T3 
level accompanied by very low or undetectable levels  of 
TSH(42). 
• Treatment(44): 
1) Medical treatment:  Propythiouracil (PTU) or 
methimazole  
 - Propanolol: for control of symptoms while 
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another mode of therapy exerts its effect. 
2) Surgery:  Subtotal thyroidectomy . 
1.15  Effects of anti-epileptic drugs on 
thyroid function: 
 Since 70th, the side effects of antiepileptic drugs on 
the endocrine system are being reported (45,46).  
 Metabolism plays a key role in regulating the 
biological activity of many hormones.  In the case of thyroid 
hormones, a number of important metabolic pathways 
interact to balance synthesis, bioactivation, and 
deactivation(47). 
 Because drugs, industrial chemicals and chemicals of 
environmental importance can increase thyroid hormone 
metabolism, it is important to consider the impact these 
compounds have on thyroid hormone and thyroid gland 
homeostasis(48). 
 Thyroid hormones levels are regulated at the levels of 
synthesis and secretion by the thyroid gland and also 
metabolism in the periphery(48). 
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 As mentioned before thyroid hormones are 
synthesized and secreted under the influence of the 
hypothalamus – pituitary – thyroid axis(40).  
 The principal pathways of peripheral thyroid hormone 
metabolism are deiodination and conjugation to glucuronic 
acid or sulfate(48). 
 Conjugation of thyroid hormone involves 
glucuronidation or sulfation of the phenotic hydroxyl group, 
which increases water solubility(49-51). Sulfation also 
inactivate thyroid hormones(52). 
 The phase II drug metabolizing enzymes uridine 5’ 
diphosphate – glumuronosyl transferase (UGT) and 
sulfotransferase (SULT) mediate glucuronidation and 
sulfation of thyroid hormone.  Induction of these enzymes 
by the widely used antiepileptic drug phenobarbitol (PB) 
and other xerobiotics increases thyroid hormone 
metabolism and decreases TH levels in both animals and 
humans(51-54). 
 The nuclear hormone receptor constitutive 
andrestane receptor (CAR) mediates the induction of 
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hepatic drug metabolism in response to PB and other 
xerobiotics(55,56).  Thus the loss of CAR in mice results in the 
complete absence of CCY2B10 induction in response to PB 
and PB like inducer in the liver and decreased 
drug-metabolizing capability. 
 Recently the list of CAR target genes has been 
expanded to encompass genes involved in all phases of 
xerobiotic metabolism, including the CYP3A enzymes, 
UGTIA as well as SULT2A & SULTIA and the multidrug 
resistance associated protein family of transporters (57).  
Many of these genes are also involved in TH metabolism 
(58-61). 
 Antiepileptic drugs change circulating hormones 
concentration (62-64) and also pituitary responsiveness to 
various stimuli (65-66). 
 The level at which the antiepileptic drugs affect the 
endocrine system is not certain (67).  The influence of 
phenytoin and carbamazepine on the thyroid hormone has 
both interested and confused clinicians and investigators 
for more than three decades. 
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 The first study about the effects of antiepileptic drugs 
on thyroid gland was made in 1961 by Oppenheimer et al.  
They found that phenytoin treatment reduces thyroid 
hormone concentration in patients with epilepsy (68,69).  
Moreover, since 1970 it has been obvious that 
carbamazepine therapy also changes the thyroid hormones 
balance in epileptic patients (70-72). 
 Since then several studies have been reported about 
the toxic effects of antiepileptic drugs on thyroid glands 
(67,73,75,77-84).  It was found that some antiepileptic drugs 
decrease thyroid function certainly for example; phenytoin 
and carbamazepine clearly decrease thyroid function but 
does not change the euthyroid state.  It has been reported 
that these drugs decrease the free serum thyroxine 
concentration (FT4) but not change the serum FT3 and TSH 
level (76, 77). 
 Concerning mechanisms by which anti-epileptic 
drugs affect the thyroid hormones concentrations. 
 Oppenhimier(68) et al reported that serum protein 
bound iodine concentration was significantly decreased in 
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patients treated with phenytoin. 
 In vitro studies showed that phenytoin competed 
reversibly with thyroxine (T4) for binding sites on serum T4 
binding globulin.  These findings would predict that serum 
free T4 concentration should be normal in phenytoin 
treated patients.  However, Chin & Schussler (85) and then 
Larsen et al (86) using ultra-filtration assay, reported that 
serum FT4 was actually decreased in phenytoin treated 
patients.  Their findings were supported by many other 
investigations that used a variety of methods to determine 
serum T4 concentration and were extended to patients 
treated with carbamazepine as well.  
 On the other hand Martin(87), et al re-evaluated the 
effect of phenytoin and carbamazepine on serum FT4 
hormone concentration using an ultra-filtration assay for 
FT4 and FT3 fraction.   This hypothesis is that therapeutic 
concentrations of these drugs displace thyroid hormone 
from their serum binding proteins resulting in normal FT4 
hormone concentration.  Moreover, he anticipated that the 
effect of these drugs on the interaction between the 
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iodothyronines and their serum binding protein would be 
lost upon dilution of serum(87-89). 
 Generally, Phenobarbital, phenytoin and 
carbamazepine are called as “enzyme-inducing 
antiepileptic drugs” because of their activating effect on 
hepatic microsomal enzyme system (67). 
 Despite the decreased serum T4 and F T4 levels during 
the carbamazepine treatment, the patients didn’t show any 
obvious signs of clinical hypothyroidism and no significant 
increase of the mean serum TSH concentration.  Also 
serum T3 concentration was unaffected by carbamazepine 
therapy although possibly the conversion of T4 and T3 is 
also increased by enzyme-induction during carbamazepine 
therapy (65).  Moreover, one article suggests that 
carbamazapine may also have direct inhibitory effects on 
iodide uptake and hormone synthesis in the thyroid 
glands(90). 
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  Justifications 
 
 
? Number of children taking anticonvulsant drugs is 
increasing. 
? No previous study was done to investigate the effect 
of antiepileptic drugs on thyroid function in 
Sudanese children. 
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 Objectives 
 
 
? To study the effect of antiepileptic drugs (Sodium 
valproate and carbamazepine) on thyroid function in 
Sudanese epileptic children. 
? To determine the variation in thyroid function in 
patients treated with these drugs as far as age, sex, 
origin and duration of treatment are concerned. 
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Chapter Two 
2.  Material and Methods 
2.1 Nature of the Study: 
A cross sectional hospital based study.  
2.2 Study Area: 
The study was conducted in Gaafar Ibn Auf Children’s 
Hospital and Omdurman Children’s Emergency Hospital at 
the referred clinics. 
2.3 Duration of the Study: 
The study was conducted in the period from April – 
July 2006. 
2.4 Study Population: 
The study populations were known epileptic children 
attending the referral clinics of Gaafar Ibn Auf Children’s 
Hospital and Omdurman Teaching Hospital.  All children 
were below 16 years, they were on CBZ or Sodium 
valproute for > 6 months. 
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2.5 Sample Size and Sampling Technique: 
2.5.1 Inclusion criteria:  All children <16 years of age 
with diagnosis of epilepsy clinically and by EEG and who 
were maintained on regular carbamazepine or sodium 
valproate for > 6 month. Inclusion agreed after taking 
verbal consent from parents or care- giver.  
2.5.2     Exclusion criteria:   
? Patients with cerebral palsy 
? Epileptic patients taking other antiepileptic 
drugs 
? Patients with progressive cerebral disorders 
? Patients with other chronic diseases eg: DM, 
chronic RF, etc. 
? Patients on other long term medication that 
could affect thyroid function. 
? Patients who (or their care taker) refused to 
participate in the study. 
? Non-complaint patients. 
? Patients on polytherapy. 
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2.5.3 Sample size: 
All patients were presented to the study area with the 
diagnosis of epilepsy during the period from 1st  April to 30th 
July and fulfilling the entry criteria were included in the 
study, they were 67 patients. 
The control group included healthy children and 
children with simple upper respiratory tract infection who 
presented to the out patient department.  They had no 
chronic disease and did not receive any drugs during the 
last two weeks prior to blood sampling.  This group 
consisted of 30 cases 18 males and 12 females. 
2.6 Study Technique and Tools: 
2.6.1 Research team: 
o The author 
o A lab technician 
2.6.2 Research tools: 
2.6.2.1 Questionnaire containing the following data: 
o Personal data 
o History of the disease and treatment 
o Symptoms of hypothyroidism 
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2.6.2.2   Clinical examination 
a) General examination 
b) Signs of hypothyroidism 
2.6.2.3   Laboratory methods: 
Total T3,total T4 and TSH were measured using RIA. 
• Methods of reading total T4:  
 T4 RIA method depends on the competition between 
Iodine125 labeled T4 and T4 contained in standard or in 
specimens to be assayed, for a fixed and limited number of 
T4 antibody binding sites.  After the incubation, the 
amount of Iodine   125 labeled T4 bound to the antibody is 
inversely related to the amount of T4 present in the sample 
 In the antibody suspension of kits used, the antibody 
is covalently bound to magnetisable particles.  Separation 
of antibody bound fraction is achieved by magnetic 
separator and discounting the supernatant, by measuring 
the proportion of Iodine 125 labeled T4 bound in the 
presence of reference standards containing various known 
amounts of T4.  The concentration of T4 in known samples 
can be interpolated.  
 38
 The sensitivity was calculated as the concentration 
which is two standard deviations above the zero standards.  
The sensitivity is above 4 mcg/ml. 
• Methods of TSH readings: 
 CI AE TSH IRMA kit utilizes two site sandwich 
immunoradiometric assays for the measurement of TSH in 
human serum.  This involves the reaction of TSH present in 
serum with monoclonal and polyclonal antibody.  The 
monoclonal antibody is labeled with Iodine 125 as tracer 
(I125 – Mc Ab) and the polyclonal antibody is completed to 
magnetic iron oxide particles (PcAb < M>).  The formed 125 
I-McAb-TSH-PcAb <M> complex (sandwich) is separated 
from unbound tracer by placing the assay tube in the 
magnetic separator and decanting supernatant.   The 
radioactivity of tracer in the tubes is directly proportional to 
the cone of TSH in the specimen. 
 The sensitivity of the assay is 0.04 ml U/L.  It was 
calculated as the concentration. Which was two standard 
deviations above the zero standard. 
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• Method of total T3 reading: 
 The RIA method depends on the competition between 
Iodine125 labeled T3 and T3 contained in standards or in 
specimens to be assayed, for a fixed and limited number of 
T3 antibody binding sites.  After the incubation, the 
amount of 125 I-labeled T3 bound to the antibody is 
inversely related to the amount of T3 present in the sample. 
By measuring the proportion of 125 I-labeled T3 bound in 
the presence of reference standards containing various 
known amounts of T3, the case of present in unknown 
samples can be interpolated.   
2.7 Data Analysis: 
Data was analyzed using computer program.  The 
Statistical Package of Social Sciences System (SPSS) and 
chi square and student T-test. 
Results were expressed as mean .The level of 
significance of difference between mean values among 
cases and control group were determined by the Student 
independent test, with P<0.05 considered significant. 
Thyroid hormones levels were categorized in ranges 
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(Normal, low, and high) according to standard level 
according to age: 
T3level (nmol/l): 
      1-5Yrs     : 1.45-4.0 
      5-10yrs   : 1.93-3.7 
     10-15yrs: 1.2 - 3.2 
      >15yrs    :1.7 - 2.9 
T4 level (nmol/l): 
      1-3yrs    : 88 -174 
      4-10yrs: 71- 165 
       >10yrs   : 54-176  
      TSH level (mlU/l) :  
             5mon-20yrs: 0.7-6.5 
Taking in consideration values lower than the lower   
limit as (low), values within the normal range as 
(normal),and values higher than the upper limit as (high) . 
With a value corresponding to P<0.05 for significance. 
testing of difference between proportions was conducted 
using the Chi-square test. 
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2.8 Ethics: 
- Verbal consent was obtained from all parents or 
accompanying care takers of children in the study (i.e. 
both cases and control groups). 
- Doctors in charge were informed about the results. 
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Chapter Three 
3. Results 
      A total of 67 children  with  epilepsy  and 30 normal    
children  ,age <16  years  were  enrolled  in  the  study.  
Data was collected and a master sheet was performed.  The 
data was analyzed using statistical package of social 
sciences, a soft program.  
3.1 Socio-demographic Characteristic: 
3.1.1 Age and sex characteristic of the study: 
The mean (+ SD) age of cases group in this study was 
9.96 + 3.349. While the mean age group of control group 
was 9.63(3.4) P=0.57.The majority of cases in both groups 
were between 5-15years as shown in (Figure 1).      
Regarding sex characteristic, males were 
predominate in cases groups as shown in (Figure2)                        
3.1.2   Origin and residence: 
Majority of the patients were from central tribes as 
shown in (Figure 3).And most of them reside in the capital 
(Figure 4). 
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3.2 Description of Seizures in the Study Group: 
3.2.1 Type of epilepsy in children in the study group: 
The majority of children in the study were classified 
as having generalized convulsions 50 (74.7%).  42 (84%) of 
them were grandmal epilepsy, 4(8.0 %) ronaldic and 4 
(8.0%) were absence.  Focal epilepsy were 9 (13.4%) and 
8(11.9 %) children were having combination of more than 
one type. (Figure  5 ) 
3.2.2 duration of the disease:  mean(SD) duration of 
illness was 4.3(.04) years for CBZ group and 3.7(0.7) years 
for VAP group. The duration of illness in the majority of 
children , was1-5.(Table 1).     
3.2.3 Modality of treatment:  56 (83.6%) are on    
carbamazepine while only 11 (16.4%) are on sodium 
valproate. (Figure  6) 
3.2.4 Duration of treatment: duration of treatment 
in most patients in CBZ group was <18 months and it was 
18-36 months for VAP group (Table 2). 
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Table (1):  Distribution of cases group according to 
duration of illness 
 
Duration of VAP group CBZ group 
 49
illness 
(Years) 
NO % NO % 
< 1 0 0.0 4 7.1 
1-5 6 54.5 30 53.6 
> 5 5 45.5 22 39.3 
Total 11 100.0 56 100.0 
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Table (2):  Distribution of patients according to 
duration of treatment 
 
VAP group CBZ group Duration of 
treatment 
(Months) 
NO % NO % 
< 18 3 27.3 27 48.2 
18 – 36 7 63.6 14 25 
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> 36 1 9.1 15 26.8 
Total 11 100.0 56 100.0 
 
 
 
 
 
 
 
 
 
3.3 Thyroid hormone level in cases and control:  
Table 3: Shows that CBZ group had significant higher T3 
and significant lower T4 than the control group. However 
the level of TSH was not significantly in CBZ and control 
groups. 
Table 4: Shows no significant difference between VAP 
and control groups. 
Table 5: Shows most of the patients of CBZ group have 
normal T4 level and a significant number have lower 
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level. 
Table 6: Shows that the percentage of T4 level was not 
different between VAP and control groups. 
Table 7: Shows almost half of the CBZ groups have lower 
T3 level.  
 Table 8:  Shows that although there is high percentage 
of patients with low T3 level, there is no significant 
difference between VAP and control groups.  
Table 9: Shows no different percentage in serum TSH 
level between CBZ and control groups.  
Table 10:  Shows no different percentage in serum TSH 
between VAP and control group 
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Table (3):  Thyroid function in CBZ and control groups 
 
 CBZ group Control group Thyroid function 
test 
  
 
Mean(SD) 
 
Mean(SD)   
 
 
P. 
value 
 
 
Serum T3 
(nmol/l) 
 
1.56(0.89) 
 
1.22(.38) 
 
0.04 
 
Serum T4     
(nmol/l) 
 
76.0(22.87) 
 
101.4(22.45) 
 
0.002 
 
Serum TSH 
(mlU/l) 
 
2.84(1.45) 
 
2.54(1.70) 
 
 
0.42 
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Table (4): Thyroid function in VAP and control groups 
 Control group VAP group  Thyroid 
function  
  
Mean(SD) Mean(SD) 
P 
value 
 
Serum T3 
  (nmol/l)      
 
1.22(.38) 
 
1.24(0.49) 
 
0.87 
 
Serum T4 
 (nmol/l)  
 
101.4(22.45) 
 
 
89.78(27.58) 
 
0.20 
 
Serum TSH 
(mlU/l) 
 
2.54(1.70) 
 
 
3.04(1.44) 
 
 
0.39 
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Table (5):  Serum total T4 level in patients on CBZ and 
control groups 
 
Study group 
CBZ group Control 
 
T4 level 
NO % NO % 
 
Low 
 
18 
 
32.1 
 
1 
 
3.3 
 
Normal 
 
37 
 
66.1 
 
29   
 
96.7 
 
High 
 
1 
 
1.8 
 
0 
 
0.0 
 
Total 
 
56   
 
100.0 
 
30 
 
100.0 
 
                                           P=0.005 
 
 
Table (6 ):  Serum total T4 in patients taking Sodium 
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valproate and control groups 
 
 
Study group 
VAP group Control 
 
T4 level 
NO % NO % 
 
Low 
 
1 
 
9.1 
 
1 
 
3.3 
 
Normal 
 
10 
 
90.9 
 
29   
 
96.7 
 
High 
 
0.0 
 
0.0 
 
0.0 
 
0.0 
 
Total 
 
11   
 
100.0 
 
30 
 
100.0 
 
 
                                       P=0.95 
.    
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Table (7):  Serum T3 level in patients on CBZ and control 
groups 
Study group 
CBZ group Control 
 
T3 level 
NO % NO % 
 
Low 
 
25 
 
44.6 
 
20 
 
66.7 
 
Normal 
 
28 
 
50 
 
10 
 
33.3 
 
High 
 
3 
 
5.4 
 
0.0 
 
0.0 
 
Total  
 
56 
 
100 
 
30 
 
100 
 
 
                                       P = 0.09 
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Table (8):  Serum T3 level in patients taking VAP and 
control groups 
 
Study group 
VAP group Control 
 
T3 level 
NO % NO % 
 
Low 
 
8 
 
72.7 
 
20 
 
66.7 
 
Normal 
 
3 
 
27.3 
 
10   
 
33.3 
 
High 
 
0 
 
0.0 
 
0 
 
0.0 
 
Total 
 
11   
 
100.0 
 
30 
 
100.0 
 
  
                                   P=0.99  
 
Table (9): TSH in patients taking CBZ and control 
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groups 
 
Study group 
CBZ group Control 
 
Serum TSH level 
NO % NO % 
 
Low  
 
1   
 
1.8 
 
2   
 
6.7 
 
Normal 
 
54   
 
96.4 
 
27   
 
90.0 
 
High 
 
1   
 
1.8 
 
1   
 
3.3 
 
Total 
 
56 
 
100.0 
 
30 
 
100.0 
 
 
                            P=0. 
 
Table (10):  Serum TSH in patients taking VAP and 
control  
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Study group 
VAP group Control 
 
TSH level 
NO % NO % 
 
Low 
 
0.0 
 
0.0  
 
2 
 
6.7 
 
Normal 
 
11 
 
100 
 
27   
 
90.0 
 
High 
 
0 
 
0.0 
 
1 
 
3.3 
 
Total 
 
11   
 
100.0 
 
30 
 
100.0 
 
                                 P=0.55   
 
 
 
3.4:EFFE CT OF AGE AND GENDER ON THYROID 
FUNCTION; 
          Concerning the age and sex effect on thyroid 
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function , there was no effect except in the age group < 
10years in CBZ group which have lower T4 level than the 
control group=0.002  (Table 11) . 
3.5. Effect of origin and residence of the study group 
on thyroid function : 
        Regarding origin and residence of the study 
groups there was no significant difference between all 
groups in thyroid function. 
3.6:  Effect of duration of treatment on thyroid 
function: 
            Concerning the duration of treatment ,the only 
difference was that in patients who are on CBZ ,the 
percentage of patients who have low serum T3 level 
increase with the increase in duration of 
treatment .(Table12) . 
Table (11):  Effect of age on T4 in patients taking CBZ 
 
CBZ group  Serum T4 
level <10 yrs >10yrs 
 62
NO % NO % 
 
Low  
 
13 
 
48.15 
 
5 
 
17.2 
 
Normal 
 
13 
 
48.15 
 
24 
 
82.8 
 
High 
 
1 
 
3.70 
 
0 
 
0.0 
 
Total 
 
27 
 
100.0 
 
29 
 
100.0 
 
 
                                    P=0.002 
 
Table (12): The effect of duration of treatment on T3 in 
patients taking CBZ  
Duration  of 
treatment 
 
      Low   
 
normal 
 
high 
 
total 
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(months)    
No  
 
% 
 
no 
 
% 
 
No  
 
% 
 
No  
 
% 
 
        <18   
 
10 
 
37.0 
 
15 
 
55.6 
 
2 
 
7.4 
 
27 
 
100.0 
       
      18-36 
 
6 
 
42.9 
 
7 
 
50 
 
1 
 
7.1 
 
14 
 
100.0 
 
       >36 
 
9 
 
60.0 
 
6 
 
40 
 
0 
 
0.0 
 
15 
 
100.0 
 
 
P=0.042 
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The effect of antiepileptic drugs on thyroid function is 
known for along time. There seems to be considerable 
individual variability of response to antiepileptic therapy, 
probably depending on peripheral changes in the hormone 
metabolism (90)  
As in children, thyroid hormones are important for 
normal mental and physical growth, the study of the effect 
of antiepileptic drugs on thyroid function is important.  
   Our study was carried out in 67 Sudanese epileptic 
children  with age less than 16years , with predominance of 
male sex as in the studies done by Amani( 91 ) and Khalid( 
8  ) .The controls were 30 healthy children who came to the 
causality with upper respiratory infection or as co-patients 
.It was difficult to find the ideal control group which should 
either be epileptic patients with no treatment ,or the same 
patients before and after treatment .   
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Mean (SD) of age was not significantly different between 
cases and controls showing good matching between the two 
groups (P=0.57) . 
The predominant age group was 10.0 -15years as was 
found by Amani(91). 
Like in Amani's(91) study the majority of cases in our 
study group 44.3%  were from central tribes. And the 
majority of them reside in the capital. 
Generalized seizures were the commonest type of 
epilepsy in our study group .Also this result was obtained 
by Amani(91) and Khalid (8) . 
. The majority of patients in our study were on CBZ 
while small number of patients (16.4%) were on VAP, and 
the mean (SD) duration of treatment for VAP in our study 
was almost half of that of CBZ, and these were the only 
patients who attended the referred clinics and fulfilled the 
criteria of our study group .While in Kirimi's (80) study 
group it was almost the same in VAP and CBZ. 
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Serum total T4 level had significant lower level in 
CBZ than control group P=0.005. While there was no 
significant difference between VAP and control group 
P=0.20. This could be due to enzyme induction, which 
lead to increase in thyroid hormone metabolism and 
decrease in thyroxine level. 
 This result was consistent with the previous studies 
of: Caksen (89) who found that, there is low T4 and FT4 in 
patients treated with CBZ for a long time. Similar results 
were obtained by Yuksel et al (81). 
Verma and Haidukewych (82), assessed the 
differential effects of AEDs on hepatic enzymes and 
thyroid hormones levels in 317 patients, they found 
significant different between control and these drugs 
and this is consistent with our study. Connacher, et 
al (83) in their study in 71 epileptic patients, T4 was 
normal in 40% of patients on CBZ and 85% in that 
who were on VAP.  
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 .Yong-Won,et al also studied 45 patients who 
were on long term AED therapy and 45 control, they 
concluded that FT4level was lower only in patients 
taking enzyme inducing AEDs compared to control 
group.  Larkin (77) et al also studied thyroid function 
in 54 epileptic patients, also they found that serum 
total T4concentration were reduced in patients taking 
enzyme-inducing drugs(CBZ or/and Phenytoin ) 
compared with both control and patients taking VAP . 
Rozza et al (94) also concluded the same results. 
De Luca et al(95) ,who studied T4, and FT4 in five 
hypothyroid children with partial epilepsy receiving 
L.Thyroxin .They found that serum total T4 and FT4 
significantly decreased following 2 months of CBZ  
administration . 
 Among the studies searching the effect of 
antiepileptic drugs on thyroid hormones ,the best and 
most consistent results are obtained with Valproate which 
doesn't change the thyroid hormone levels because it is 
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not an inducing drug(67) .Isojarvi et al reported that there 
was no significant difference between Valproate and 
control groups, and this is consistent with our study  . 
Haidukewitych and Rodin(76)and Kirimi(80) et al reported 
the similar result to our study.  
In contrast to our study, Ericsson et al (79) reported 
high total T3 and total T4 but normal TSH levels.  
Because the number of patients taking VAP in our 
study was small we can not definitely compare to other 
results and may be we need other studies with large 
number of patients. 
Although there was significant difference between 
CBZ and control groups, in T4level, such a difference was 
not obtained between CBZ and VAP groups. This may 
mean that VAP does not lower T4 level to a statistically 
significant level. But there was no other study in literature 
review comparing CBZ and VAP. 
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Serum T3 level was significantly higher in CBZ group 
than control group .But it was not different between VAP 
and control groups in our study. 
All previously mentioned authors found that 
administration of CBZ and VAP did not alter serum T3 
level, except for Kimura (96) who found that serum T3 
levels were reduced after CBZ discontinuation .They 
suggested that during treatment serum T3 level was 
increased and this could be due to an increased 
conversion of T4 to T3. There was no difference between 
VAP and control groups; and this is consistent with our 
study. Ericsson et al (79) also found high T3 level .Eiris –
Punal(78) ,Liewendehl (69),and Gometic(97) found low T3 
and /or rT3 . 
 In our study , although the mean(SD) of T3 level in 
CBZ group was higher than the control ;the percentage of 
patients who had low T3 levels increase with the increase 
of duration of  treatment  ,this can be explained by 
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increase in T4 metabolism and increase in peripheral 
conversion of T3 toT4. 
There was no significant difference between serum levels 
of T.S.H. in CBZ or VAP group than the control group in 
our study .And this is consistent with the results of other 
investigators ,except Eiris-Punal(78) and Vainionpaa et 
al(92) who found increased serum T.S.H. levels(P<0.01) 
Those patients <10years had significant lower T4 than 
those >10years group.In literature review we didn't find any 
author who studied this effect. I think this is because 
children less than ten years are more vulnerable to other 
factors which can affect thyroid function in addition to this 
drug (e.g. nutrition) . 
Sex and origin of the patients had no effect on thyroid 
function. 
In our study and as was found by Isojarvi (63) our 
patients with low T4 had normal thyroid gland this suggest 
a hypothalamic interference caused by CBZ therapy.  
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It remains to be established whether epileptic patients 
receiving CBZ therapy are really suffering from a sub 
clinical hypothyroid state caused by the increased 
metabolism of thyroid hormones. 
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                            CONCLUTION
 
? The study population were epileptic children 
with age group below 16 years ;the 
predominant sex was males ;and they were on 
CBZ or VAP for > 6months . 
? Serum total T4 levels were found to be 
significantly low compared to control group in 
patients taking CBZ .While it has no difference 
from control group in patients taking VAP . 
? T3 has significant higher levels in CBZ group 
;while it has no difference between VAP and 
control groups . 
? T.S.H. levels has no significant difference 
between both groups and  control group . 
? Serum T4 was found to be affected by age , but 
not affected by sex ,origin of the patients or 
duration of treatment  . 
? Serum T3 was found to be affected by duration 
of treatment in CBZ group, but was not 
affected by sex , age or origin . 
? Almost all patients were found to be clinically 
euthyroid  
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                           Recommendations   
                     
 
? Initiation of specialized clinics for epileptic patients                                  
? Basal thyroid function test should be performed for 
every candidate for AEDs, e.g. CBZ.                                                           
? To make thyroid function test less expensive and 
attainable for all epileptic patients. 
? In known cases of hypothyroidism, and those with 
altered basal thyroid function test, CBZ should be 
prescribed cautiously.  
? We suggest further studies involving larger number of 
patients to elucidate more the effect of AEDs on 
thyroid function. 
? To elucidate the effect of AEDs on thyroid function, 
thyroid function should be done before and during the 
treatment.                                                    
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o To elucidate the effect of AEDs on thyroid function, 
thyroid function should be done before and during the 
treatment.                                                    
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o To make thyroid function test less expensive and 
attainable for all epileptic patients. 
o In known cases of hypothyroidism, and those with 
altered basal thyroid function test, CBZ should be 
prescribed cautiously.  
o We suggest further studies involving larger number of 
patients to elucidate more the effect of AEDs on 
thyroid function. 
o To elucidate the effect of AEDs on thyroid function, 
thyroid function should be done before and during the 
treatment.                                                    
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Postgraduate Medical Studies Board                     
Questionare                                                
 
 
 
Serial No:                                                                                
Unit:                                                                                         
hospital :                                                                                  
 
1)Name:------------------------------------------ 
2)Age:--------------------- 
3)Sex:-------------------- 
4)Origin:------------------- 
5)Residence:------------- 
6)Duration  of  illness:----------------- 
1)1-5yrs                                                                                      
2)5-10yrs                                                                                    
3)>10yrs                                                                                     
7)Type of epilepsy: 
1)Generalized                                                                               
2)Focal                                                                                           
3)Combination                                                                               
8)Modality of treatment: 
 1)Carbamazepine                                                                            
 2)Sodium Valproate 
 
9)Duration of treatment:--------------------- 
10) Symptoms of hypothyroidism                                                              
 
 
 
 
 
1)Cold intolerance                                                                      
2)Lethargy                                                                                  
3)Tiredness                                                                                 
4)Chang of voice                                                                         
5)Bowel habits :                                                                          
5.1)Normal                                                                  .  
5.2)Constipation.                                                            
5.3)Diarrhoea                                                                . 
6)Growth :                                                                                     
6.1)Normal.                                                                        
6.2)Littile to no growth                                                       . 
6.3) Weight gain                                                                    
 11)Family history of thyroid abnormality              
.12)Drug history: 
                                         
13)Menestural history (in females): 
13.1)Normal cycles.    
13.2)Metrorrhagia .   
14)Examination: 
14.1)General:    
14.1.1:Pallor:    
1)yes                       2)No   
14.1.2:Lethargy:      
 1)Yes                             2)No                            
14.1.3:Pulse:    
1)Normal                 2)Bradycardia   
14.1.4: Skin:    
       1)Normal            2)Dry 
14.1.5:Goitre:    
1)yes                  2)No    
15)Anthropometric measurements: 
15.1:Weight(kg)                                                                                    
15.2:Height (cm)                                                                                    
16)Other systems                                                                                          
1)normal                2)Abnormal(specify)                                              
17)Investigations: 
17.1:Serum T4 level .                                                                                 
17.2:Serum T3 level.                                                                                  
17.3:Serum T.S.H. level                                                                             
                        
                                                                                
                                                                                    
       
 
